Skip to main content

Table 1 Baseline characteristics of patients

From: Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis

Characteristics

Training cohort

Validation cohort

No. of patients

%

No. of patients

%

Age(year)

  < 65

200

29.7

91

32.9

  ≥ 65

474

70.3

186

67.1

Gender

 Male

462

68.5

182

65.7

 Female

212

31.5

95

34.3

Smoking

 Smoker

490

72.7

188

67.9

 Never-smoker

184

27.3

89

32.1

PS

 0–1

211

31.3

3

1.1

  ≥ 2

463

68.7

274

98.9

T stage

 1

97

14.1

23

8.3

 2

285

42.3

135

48.7

 3

147

21.8

59

21.3

 4

145

21.5

60

21.7

N stage

 0

92

13.6

31

11.2

 1

133

19.7

60

21.7

 2

228

33.8

97

35

 3

221

32.8

89

32.1

Synchronous BM

 Yes

518

76.9

210

75.8

 No

156

23.1

67

24.2

Number of BM lesion

 1

261

38.7

107

38.6

  ≥ 2

413

61.3

170

61.4

Maximum diameter of BM lesion

  < 2 cm

360

53.4

174

62.8

  ≥ 2 cm

314

46.6

103

37.2

Extracranial metastases

 Yes

259

38.4

110

39.7

 No

415

61.6

167

60.3

Cerebral symptoms

 Yes

234

34.7

87

31.4

 No

440

65.3

190

68.6

Receiving local treatment (surgery/wbrt/srs)

 Yes

412

61.1

131

47.3

 No

262

38.9

146

52.7

Receiving chemotherapy

 Yes

517

76.7

217

78.3

 No

157

23.3

60

21.7

  1. PS,Performance Status; BM, Brain metastases; WBRT, whole-brain radiation therapy; SRS, stereotactic radiosurgery